clobetasol and Hypopigmentation

Topical superpotent class I corticosteroids (CSs) are highly effective in the treatment of early-stage mycosis fungoides (MF) and are readily available, easily applied, and have minor side effects compared to other topical therapeutic options. Because MF is a chronic disease, prolonged treatment is needed, raising the concern of CS-induced cutaneous adverse effects (AEs). In this observational study, we aimed to evaluate the risk for skin AEs of clobetasol propionate cream 0.05% in patients with early-stage MF. Thirteen consecutive patients with MF were treated with clobetasol propionate cream 0.05% once or twice daily as monotherapy and were followed for 4 to 17 months. One participant was lost to follow-up, and the remaining 12 participants responded to treatment with topical clobetasol propionate with minimal side effects. With proper education and monitoring, topical CSs are a safe and effective mainstay of treatment for patches and flat plaques in patients with early-stage localized MF.

Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Atrophy; Clobetasol; Female; Glucocorticoids; Humans; Hypopigmentation; Male; Middle Aged; Mycosis Fungoides; Prospective Studies; Skin; Skin Cream; Skin Neoplasms

Skin of color patients with psoriasis face unique challenges related to disease characteristics and treatment. Dyspigmentation, including postinflammatory hypo- and hyperpigmentation, more frequently and severely affects patients with skin of color and remains a challenge in psoriasis management. We present the case of a 58-year-old Black male with moderate psoriasis who was treated for 8 weeks with a fixed combination halobetasol propionate 0.01%/tazarotene 0.045% (HP/TAZ) lotion during a phase 3 study (NCT02462070). HP/TAZ was efficacious in this patient, whose Investigator’s Global Assessment score decreased from 3 (moderate) at baseline to 1 (almost clear) within 4 weeks, with maintenance of & "almost clear"; through week 12 (4 weeks posttreatment). Affected body surface area decreased by 50% and quality of life greatly improved from baseline to week 8. The patient experienced dyspigmentation of the affected skin during the trial; hypopigmentation was primarily experienced from weeks 2-8, with the greatest degree at week 4. By week 12, the affected skin area had returned to normal, with only small regions of hyperpigmentation, primarily around the periphery of the lesion. These results indicate that HP/TAZ may be a treatment option for patients with skin of color, who are disproportionally affected by postinflammatory dyspigmentation. \ \ J Drugs Dermatol. 2020;19(10):1000-1004. doi:10.36849/JDD.2020.5347.

Topics: Administration, Cutaneous; Black or African American; Clobetasol; Drug Combinations; Esthetics; Humans; Hypopigmentation; Male; Middle Aged; Nicotinic Acids; Psoriasis; Severity of Illness Index; Skin Cream; Skin Pigmentation; Treatment Outcome

Hypopigmented mycosis fungoides (HMF) is the most common variant of mycosis fungoides (MF) in children. Large-cell transformation in HMF has never been reported. Herein we report a case of HMF in an 8-year-old boy who presented with a 6-year history of hypopigmented patches on the bilateral arms, lower back, buttocks, posterior thighs, and lower legs. Biopsy revealed an abnormal CD8

Topics: Biopsy; Cell Transformation, Neoplastic; Child; Clobetasol; Glucocorticoids; Humans; Hypopigmentation; Male; Mycosis Fungoides; Skin; Skin Neoplasms; T-Lymphocytes; Ultraviolet Therapy

Topics: Adult; Alopecia Areata; Anti-Inflammatory Agents; Child, Preschool; Clobetasol; Dose-Response Relationship, Drug; Female; Foot Dermatoses; Hand Dermatoses; Humans; Hypopigmentation; Male; Nails, Ingrown; Nails, Malformed; Paronychia; Skin Pigmentation

A 9-year-old girl visited the department of Dermatology with an asymptomatic hypopigmented skin eruption on her upper legs, groins and trunk since 7 years. Histopathological analysis established the diagnosis of hypopigmented mycosis fungoides, a rare subtype of cutaneous T-cell lymphoma which is most commonly seen at younger age. The lesions are successfully treated with clobetasol 0.05% ointment 4 days a week.

Topics: Child; Clobetasol; Female; Glucocorticoids; Humans; Hypopigmentation; Mycosis Fungoides; Skin Neoplasms; Treatment Outcome